This technology is used to reveal the immune profiling of the tumor microenvironment based on multi-color immunohistochemistry staining. Each immune cell type will be probed with different fluorophores,the density, as well as the location of each immune cell type on the tissue slides, will be disclosed using inForm software.

We designed a cascade spiral microfluidic device (i-Finity®)continuously isolated the unlabeled cancer cells from blood samples without lysing processes. The results showed that the i-Finity® device excluded a high percentage of RBCs in the first stagerecollected the cancer cells in the second stage. The i-Finity® device can efficiently enrich the cancer cells more than 1000 times in 10 minutes, which substantially curtailed sample preparation timeimproved the accuracy of diagnosis.

Endometriosis is a serious gynecological disease with a global incidence of 10. This disease will have a serious impact on women’s daily lives, including severe abdominal pain, massive organ bleeding, sexual behavior difficulties, infertility,even high-risk cancer progression. We discover that the karyotype variation of ribosomes is closely related to the deterioration of endometriosis. We collaborate with Hospital on human clinical trials to develop in vitro diagnostic devices that can screen early stage of Endometriosis. It can avoid unnecessary riskscosts of discovering diseases.

The innovative technology is based on the unique biomimetic material, including immunomagnetic nanoparticlesa portable IoT detection device, promoting the detection speed, accuracy,precision of the target molecule. Featuring with the excellent ability of minimizing the non-specific binding, this technology decreases false negative/false positive successfully. The device combines IoTAI module for statisticscalculation on the cloud for building up a magneto-electrochemical IoT sensing system for the integrated isolationprofiling of extracellular vesicles from plasma.

We have identified a series of BPR1R compounds as highly selective CSF1R inhibitors with excellent oral bioavailability. In vivo, oral administration of BPR1R compounds delayed murine colon tumor growthreversed the immunosuppressive TME with increased M1/M2 ratio. The US & PCT patent application including more than 160 novel compounds was filed in April 20, 2020. Several potential compounds are undergoing candidate assessment for further preclinical studies.

Our present invention firstly provides a new ultrasound (US)-multifunctional microbubble (MB) which can be applied to a topical region of the body surface of organisms by applyingsputtering, instead of using injection. Some interesting topics have been explored: 1. US-aided MBs facilitate the delivery of drugs to the inner ear via the transcanal method, 2. drug-carrying modified MB combine wit

The RL model develops a control policy directly from experience to predict statesrewards during a learning procedure. Hence, we designed a medical image environment including US images, different actions,rewards, agent learns in this environment to extract the ALN regionevaluates the status. The performance of our proposed method achieves an accuracy of 83.6, a sensitivity of 88.6,a specificity of 89.0.

This technology is a development drug lead aiming to meet the medical needs of patients with small cell lung cancer. Through disturbing MYC-Aurora A interaction and inducing degradation of MYC oncoprotein, this bioavailable kinase inhibitor could serve as a potential treatment entity for SCLC.

This project will establish a National biobank consortium of Taiwan (NBCT) through the fund supportgovernance from the government. All Alliance will follow the same SOP for the biomaterial collectionhave the same quality of the biosample. Adequateconsistent clinical data will also be established under well information security management. Since the contents of the biobanks from different institute are quite different, we will be able to quickly establish a largecomprehensive biobank network. In line with the needs of biotechnology pharmaceutical, artificial intelligence, auxiliary medicalother industries.

These stimuli-switchable nanoparticles coated with the cleavable outer polymer coatingmultifunctional peptides may afford a new platform for anticancer drugmiR. These nanoparticles possess characteristics of environmental response, active targeting,gene/chemo combinatorial therapeutics, thus providing spatiotemporal control of posttranｓｃｒｉｐｔional gene regulation, smart nuclear/mitochondrial localization,simultaneous inhibition of multiple progression pathways of tumor cells for enhancing antitumor efficacysafety of cancer therapy.

Gene delivery technology is widely used in cell therapy, nucleic acid-based vaccines, protein production, gene therapy, etc. We have developed a non-viral gene delivery technology-MPGene, which has excellent gene delivery efficiency (50-80) for human mesenchymal stem cells,also has the characteristics of low production costhigh safety. In the future, MPGene has the potential to be used in important biomedical fields such as gene delivery reagents, major trauma cell therapy, malignant tumor treatmentcartilage cell therapy.

Our system is achieved by integrating diffractiondeep learning methods, which allows high-throughput lensless imaging system to display wide rangehigh-resolution images. In addition, the developed extraction chipsprototype were verified to accurately detect the numberproportion of blood cells under low blood demand. Our system shows great potential in point-of-care blood cells monitoring for cancer patients that could reduce infection riskmortality rate, increase efficacy of chemotherapysupport precision medicine.

Cancer is the first leading cause of death in Taiwan. Targeted therapy allows the cancer cells to be specifically targeted, reduces the side effects,achieves the purpose of precision cancer treatment. This report contains two invention technologies which combined early & specific diagnosis of a specific Aurora-A mRNA isoform in cancers (the companion diagnosis)the treated with a selective locked nucleic acid (LNA)-modified novel double-stranded short interfering nucleic acid (siRNA) to inhibit the translation of this Aurora-A mRNA isoform (targeted therapy) in cancers.

The present invention discloses the germplasm bank of medicinal coral producing new targeted anti-cancer agent and their aquaculture technology platform. The medicinal corals are collected in Kenting, located at the southern tip of Taiwan. In response to the unmet medical needs of new anti-cancer drugs, our research results will provide more diverse types of new drug targets and lead compounds in the "new drug development-new drug discovery and exploration period".

Effectively inducing cytotoxic T cell expansion has been a critical challenge in vaccine development. To address this challenge, an entirely biodegradable polymeric nanoshell was invented to couple antigensadjuvants for safepotent immune potentiation. The invention has been adopted for precision anticancer vaccine, broadly reactive influenza vaccine,an effective vaccine MERS-CoV.

MPT0G211 is a highly selective HDAC6 inhibitor, with comprehensive IP protection. MPT0G211 is mainly focused on multiple myelomabrain tumor indications. For IND package, we have completed CMC in drug substance, CMC in drug product, ADME,most preclinical toxicology studies, only the 28-days repeated dose toxicology study in dog is left. Once the 28-day repeated dose toxicology study in dog is completed, the IND package will be filed in the United StatesTaiwan in Q2 2022.